Xeris Biopharma announced a total revenue of $163.9 million for the fiscal year ending on March 6, 2024. The company is projecting a full-year revenue forecast ranging from $170 million to $200 million.
Furthermore, Xeris Biopharma is expecting its year-end cash reserves, including cash equivalents and short-term investments, to be in the range of $55 million to $75 million.
Xeris Pharmaceuticals, Inc. (XERS) Stock Analysis: Positive Price Momentum and Market Trends – March 6, 2024
On March 6, 2024, Xeris Pharmaceuticals, Inc. (XERS) showed positive price momentum as it traded in the middle of its 52-week range and was above its 200-day simple moving average. This indicates that the stock has been performing relatively well compared to its historical price levels over the past year.
The price of XERS shares increased by $0.04 since the market last closed, representing a 1.32% rise. The stock closed at $3.08, showing a modest increase in value. However, in pre-market trading, the stock has dropped by $0.08. This drop may be attributed to various factors such as market sentiment, news events, or overall market conditions.
Investors should keep an eye on XERS stock throughout the trading day to see how it performs. It is essential to consider the company’s fundamentals, news, and overall market trends when making investment decisions. While short-term price fluctuations are common in the stock market, it is crucial to focus on the long-term potential of the company when evaluating investment opportunities.
As with any investment, it is important to conduct thorough research and consider your risk tolerance before making any decisions. Keep track of XERS stock performance and stay informed about any developments that may impact the company’s future prospects.
XERS Stock Sees Significant Revenue Increase: A Positive Outlook for Future Growth
On March 6, 2024, XERS stock experienced a significant increase in total revenue compared to the previous year and the last quarter. According to data from CNN Money, the total revenue for XERS was $110.25 million over the last year, representing a 122.32% increase from the previous year, and $48.32 million in the last quarter, reflecting a 27.13% increase from the previous quarter. XERS also saw improvements in net income, with a net loss of $94.66 million over the last year, which was a 22.87% improvement from the previous year, and a net loss of $12.19 million in the last quarter, showing a 38.57% increase from the previous quarter. Earnings per share (EPS) for XERS also demonstrated positive growth, with an EPS of -$0.70 over the last year, marking a 55.06% increase from the previous year, and an EPS of -$0.09 in the last quarter, indicating a 38.89% increase from the previous quarter. Overall, these financial indicators suggest that XERS has been making progress in increasing its revenue, improving its net income, and enhancing its earnings per share. Investors may view these positive trends as a sign of the company’s potential for future growth and profitability. It will be interesting to see how XERS stock performs in the coming days and whether it can sustain this positive momentum.
